European Alzheimer's experts not sold on new Eisai, Biogen drug
Biogen’s shares could be active after some Alzheimer's disease experts in Europe said the benefits of the drug did not outweigh the risks or cost. For more, follow IGTV financial analyst @Angeline Ong on Twitter.

Related articles
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.